EyePoint Inc. (NASDAQ: EYPT) saw an insider purchase by its president and chief executive, Jay S. Duker, who acquired 1,500 shares of the companys common stock on March 16, 2026. The shares were bought at $13.1492 apiece, bringing the total cost of the transaction to $19,723.
The timing of the purchase came after the stock fell 16% in the prior week. Despite that short-term pullback, EyePoint's share price has appreciated strongly over the last year, rising more than 102%.
Following this transaction, Duker directly holds 77,752 shares of EyePoint common stock. In addition, 100,665 shares are held indirectly through a family trust. EyePoint shares were trading at $13.44 at the time the data was reported, and the company had a market capitalization of $1.13 billion.
EyePoint also disclosed its fourth-quarter 2025 financial results, which reflected a notable deterioration in operating performance year over year. The company recorded earnings per share of -$0.81 for the quarter, missing analysts forecasts of -$0.75. Quarterly revenue declined to $0.6 million from $11.6 million in the same quarter a year earlier. For the full year, EyePoint posted total revenue of $31.4 million and recorded a net loss of $232.0 million, or $3.17 per share.
The company ended the quarter with cash, cash equivalents, and marketable securities totaling $306 million.
Analyst reaction to the company's developments has been varied but generally indicates continued interest in EyePoint's clinical programs. Guggenheim reiterated a Buy rating and set a $68.00 price target, citing favorable safety data for EyePoint's Duravyu treatment. Mizuho left its Outperform rating intact with a $36.00 price target. H.C. Wainwright raised its price target to $30 from $23 while maintaining a Buy rating. Chardan increased its target to $29 from $27 and retained a Buy rating.
These analyst actions demonstrate that despite the recent operating shortfall and the stock's short-term volatility, several firms remain constructive on the company's prospects as reflected in their maintained or increased price targets.
Summary of the transaction and financial update:
- Insider purchase: 1,500 shares at $13.1492 on March 16, 2026; total $19,723.
- Insider holdings: 77,752 shares directly owned by Duker; 100,665 shares held indirectly in a family trust.
- Recent performance and capital: stock down 16% over the prior week but up over 102% year over year; market cap $1.13 billion; latest trade price $13.44.
- Quarterly and annual results: Q4 2025 EPS -$0.81 (missed -$0.75), Q4 revenue $0.6 million versus $11.6 million a year earlier; FY revenue $31.4 million; net loss $232.0 million, or $3.17 per share; cash, cash equivalents, and marketable securities $306 million.